Lin X - Search Results

1

Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery.

Li L, Wang R, Wilcox D, Zhao X, Song J, Lin X, Kohlbrenner WM, Fesik SW, Shen Y. Li L, et al. Among authors: lin x. Gene Ther. 2012 Jul;19(7):775-80. doi: 10.1038/gt.2011.146. Epub 2011 Sep 29. Gene Ther. 2012. PMID: 21956688 Free PMC article.

2

A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors.

Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J, Huang X, Hansen TM, Dande P, Wada C, Hubbard RD, Kohlbrenner WM, Fesik SW, Shen Y. Lin X, et al. RNA. 2011 Apr;17(4):603-12. doi: 10.1261/rna.2546011. Epub 2011 Feb 14. RNA. 2011. PMID: 21321186 Free PMC article.

3

Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach.

Li L, Wang R, Wilcox D, Sarthy A, Lin X, Huang X, Tian L, Dande P, Hubbard RD, Hansen TM, Wada C, Zhao X, Kohlbrenner WM, Fesik SW, Shen Y. Li L, et al. Among authors: lin x. Mol Cancer Ther. 2013 Nov;12(11):2308-18. doi: 10.1158/1535-7163.MCT-12-0983-T. Epub 2013 Aug 13. Mol Cancer Ther. 2013. PMID: 23943805

4

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y. Lin X, et al. Oncogene. 2007 Jun 7;26(27):3972-9. doi: 10.1038/sj.onc.1210166. Epub 2006 Dec 18. Oncogene. 2007. PMID: 17173063

5

Development of a tightly regulated U6 promoter for shRNA expression.

Lin X, Yang J, Chen J, Gunasekera A, Fesik SW, Shen Y. Lin X, et al. FEBS Lett. 2004 Nov 19;577(3):376-80. doi: 10.1016/j.febslet.2004.10.033. FEBS Lett. 2004. PMID: 15556613 Free article.

6

siRNA-mediated off-target gene silencing triggered by a 7 nt complementation.

Lin X, Ruan X, Anderson MG, McDowell JA, Kroeger PE, Fesik SW, Shen Y. Lin X, et al. Nucleic Acids Res. 2005 Aug 9;33(14):4527-35. doi: 10.1093/nar/gki762. Print 2005. Nucleic Acids Res. 2005. PMID: 16091630 Free PMC article.

7

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.

Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, Shen Y. Li L, et al. Among authors: lin x. Cancer Res. 2005 Aug 15;65(16):7249-58. doi: 10.1158/0008-5472.CAN-04-4426. Cancer Res. 2005. PMID: 16103076

8

Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.

Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y. Li L, et al. Among authors: lin x. Clin Cancer Res. 2006 Aug 1;12(15):4747-54. doi: 10.1158/1078-0432.CCR-05-2842. Clin Cancer Res. 2006. PMID: 16899626

9

Defining the optimal parameters for hairpin-based knockdown constructs.

Li L, Lin X, Khvorova A, Fesik SW, Shen Y. Li L, et al. Among authors: lin x. RNA. 2007 Oct;13(10):1765-74. doi: 10.1261/rna.599107. Epub 2007 Aug 13. RNA. 2007. PMID: 17698642 Free PMC article.

10

A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation.

Lin X, David CA, Donnelly JB, Michaelides M, Chandel NS, Huang X, Warrior U, Weinberg F, Tormos KV, Fesik SW, Shen Y. Lin X, et al. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):174-9. doi: 10.1073/pnas.0706585104. Epub 2008 Jan 2. Proc Natl Acad Sci U S A. 2008. PMID: 18172210 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,842 results

Search Page

Filters